REFERENCES
2. Liu J, Homewood D, Rajarubendra N, Rashid P, Bolton D, Lawrentschuk N. Common incidental urological lesions on computed tomography images: what to do with renal and adrenal computed tomography incidentalomas in a primary care setting. Aust J Gen Pract. 2024;53:S47-52.
3. Radros J, Kjellman A, Henningsohn L, et al. Ablative or surgical treatment for small renal masses (T1a): a single-center comparison of perioperative morbidity and complications. Curr Oncol. 2024;31:933-40.
4. Sorce G, Hoeh B, Hohenhorst L, et al. Cancer-specific mortality in T1a renal cell carcinoma treated with local tumor destruction versus partial nephrectomy. Eur Urol Focus. 2023;9:125-32.
5. Wang M, Wilke A, Goorman S, et al; Michigan Urological Surgery Improvement Collaborative. The use of nephron-sparing intervention does not appear to be compromised after a period of active surveillance for patients with cT1 renal masses. Urol Oncol. 2025;43:268.e35-42.
6. van den Brink L, Debelle T, Gietelink L, et al. A national study of the rate of benign pathology after partial nephrectomy for T1 renal cell carcinoma: should we be satisfied? Cancers. 2024;16:3518.
7. Pandolfo SD, Wu Z, Campi R, et al. Outcomes and techniques of robotic-assisted partial nephrectomy (RAPN) for renal hilar masses: a comprehensive systematic review. Cancers. 2024;16:693.
8. Kröger Dahlin BI, Hlodan J, Ghaffarpour R, Ljungberg B. Multiple factors influence decision making for the surgical treatment in patients with renal cell carcinoma. Scand J Urol. 2024;59:26-30.
9. Lounová V, Študent V Jr, Purová D, Hartmann I, Vidlář A, Študent V. Frequency of benign tumors after partial nephrectomy and the association between malignant tumor findings and preoperative clinical parameters. BMC Urol. 2024;24:175.
10. Xing M, Kokabi N, Zhang D, Ludwig JM, Kim HS. Comparative effectiveness of thermal ablation, surgical resection, and active surveillance for t1a renal cell carcinoma: a surveillance, epidemiology, and end results (SEER)-medicare-linked population study. Radiology. 2018;288:81-90.
11. Carbonara U, Ditonno F, Beksac AT, et al. Percutaneous cryotherapy and radiofrequency ablation of renal masses: multicenter comparative analysis with minimum 3-year follow-up. Int Braz J Urol. 2025;51:e20240565.
12. Brunocilla E, Borghesi M, Schiavina R, et al. Small renal masses initially managed using active surveillance: results from a retrospective study with long-term follow-up. Clin Genitourin Cancer. 2014;12:178-81.
13. Cronan J, Dariushnia S, Bercu Z, et al. Systematic review of contemporary evidence for the management of T1 renal cell carcinoma: what IRs need to know for kidney cancer tumor boards. Semin Intervent Radiol. 2019;36:194-202.
14. Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol. 2010;57:223-32.
15. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399-410.
16. Ginsburg KB, Johnson K, Moldovan T, et al; Michigan Urological Surgery Improvement Collaborative. A statewide quality improvement collaborative’s adherence to the 2017 American Urological Association Guidelines regarding initial evaluation of patients with clinical T1 renal masses. Urology. 2021;158:117-24.
17. Jacobs BL, Tan HJ, Montgomery JS, et al. Understanding criteria for surveillance of patients with a small renal mass. Urology. 2012;79:1027-32.
18. Audenet F, Audouin M, Drouin SJ, et al. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. World J Urol. 2014;32:513-8.
19. Cheng Y, Kou W, Zhu Y. Preoperative inflammation-associated blood cell markers in patients with non-metastatic clear cell renal cell carcinoma: a retrospective study. Int J Gen Med. 2023;16:3067-80.
20. Hutterer GC, Stoeckigt C, Stojakovic T, et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol. 2014;32:1041-8.
21. Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:646-54.
22. Lee A, Lee HJ, Huang HH, et al. Prognostic significance of inflammation-associated blood cell markers in nonmetastatic clear cell renal cell carcinoma. Clin Genitourin Cancer. 2020;18:304-13.
23. Zapała Ł, Ślusarczyk A, Garbas K, et al. Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study. Front Biosci. 2022;14:5.
24. Brunocilla E, Borghesi M, Schiavina R, et al. Active surveillance for small renal masses diagnosed in elderly or comorbid patients: looking for the best treatment strategy. Actas Urol Esp. 2014;38:1-6.
25. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175:425-31.
26. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100:738-45.
27. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010;183:1698-702.
28. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180:505-8; discussion 508-9.
29. Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68:408-15.
30. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118:997-1006.
31. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma - a meta-analysis and review. J Urol. 2008;179:1227-33; discussion 1233-4.
32. Volpe A, Cadeddu JA, Cestari A, et al. Contemporary management of small renal masses. Eur Urol. 2011;60:501-15.
33. Patel N, Cranston D, Akhtar MZ, et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 2012;110:1270-5.
34. Lai TC, Ma WK, Yiu MK. Partial nephrectomy for T1 renal cancer can achieve an equivalent oncological outcome to radical nephrectomy with better renal preservation: the way to go. Hong Kong Med J. 2016;22:39-45.
35. Tanagho YS, Bhayani SB, Kim EH, Figenshau RS. Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. J Endourol. 2013;27:1477-86.
36. Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67:252-9.
